Cullinan Therapeutics Inc News - CGEM

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a...

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a...

SVB Securities Sticks to Their Buy Rating for Cullinan Management (CGEM)

In a report released on November 14, Andrew Berens from SVB Securities maintained a Buy rating on Cullinan Management (CGEM - Research Report...

Quarterly Report (10-q)

Yeshttp://fasb.org/us-gaap/2022#LicenseMemberfalsehttp://fasb.org/us-gaap/2022#LicenseMemberFebruary 01, 2018Q30001789972Yeshttp://fasb.org/us-ga...

Current Report Filing (8-k)

false 0001789972 0001789972 2022-11-14 2022-11-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Initiated pivotal study for zipalertinib (CLN-081/TAS6417) Increased ownership in MICA subsidiary, which holds...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors

CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan...

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a...

Cullinan Oncology to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan...

SVB Securities Sticks to Its Buy Rating for Cullinan Management (CGEM)

SVB Securities analyst Andrew Berens maintained a Buy rating on Cullinan Management (CGEM - Research Report) on October 25. The company's shares...

Current Report Filing (8-k)

MA false 0001789972 0001789972 2022-10-20 2022-10-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619

Cullinan increases ownership in MICA subsidiary from 54% to 92% through share purchase from existing financial...

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cullinan Therapeutics Inc (CGEM)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

CGEM News

Statement of Changes in Beneficial Ownership (4)

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SVB Securities Sticks to Their Buy Rating for Cullinan Management (CGEM)

Quarterly Report (10-q)

Current Report Filing (8-k)

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Statement of Changes in Beneficial Ownership (4)

Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cullinan Oncology to Participate in Upcoming Investor Conferences

SVB Securities Sticks to Its Buy Rating for Cullinan Management (CGEM)

Current Report Filing (8-k)

Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CGEM Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cullinan Therapeutics Inc (CGEM) News

Cullinan Therapeutics Inc (CGEM)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

CGEM News

Statement of Changes in Beneficial Ownership (4)

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SVB Securities Sticks to Their Buy Rating for Cullinan Management (CGEM)

Quarterly Report (10-q)

Current Report Filing (8-k)

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Statement of Changes in Beneficial Ownership (4)

Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cullinan Oncology to Participate in Upcoming Investor Conferences

SVB Securities Sticks to Its Buy Rating for Cullinan Management (CGEM)

Current Report Filing (8-k)

Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CGEM Discussion

Your Recent History